Blog

CAFC Says Insubstantial Differences the Test for Chemical DOE

By: Andreas Baltatzis  |   May 26, 2017

The CAFC expressly endorses the “substantial differences” test for applying the doctrine of equivalents to chemical patents, bringing clarity to "sparse and confusing case law."

Leaders and Trends in Intellectual Property: Probiotics

By: Andreas Baltatzis and Gideon B. Eckhouse  |   March 21, 2017

Successful health and nutrition companies are built on innovative products and great brands. The strongest foundation for this is intellectual property, specifically patents and trademarks. Patents protect inventions and trademarks protect brands. We discuss IP trends and highlight companies leading the creation of new products and brands in probiotics. 

Leaders and Trends in Intellectual Property: Joint Health Products

By: Andreas Baltatzis & Gideon Eckhouse  |   February 10, 2017

Successful health and nutrition companies are built on innovative products and great brands. The strongest foundation for new products and brands is intellectual property, specifically patents and trademarks. Patents protect inventions and trademarks protect brands. 

FDA Approves Amgen’s Amjevita

By: Sandy King  |   September 27, 2016

On Friday, September 23, 2016, the U.S. Food and Drug Administration approved Amgen Inc.’s Amjevita, which is the biosimilar equivalent of AbbVie Inc.’s immunosuppressant Humira. The drug is approved for more than a half-dozen conditions listed on the branded drug’s label, including severe psoriasis and Crohn’s disease.

Amgen v. Apotex Decision

By: Sandra King  |   July 18, 2016

On July 5, 2016, the Federal Circuit issued its decision in Amgen v. Apotex affirming an order preliminarily enjoining Apotex from launching its version of Neulasta (pegfilgrastim)...Apotex contended that they were not required to provide post-licensure notice to Amgen and that such requirement may not be enforced by an injunction.

Pages